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Summary  1 
 2 
Background There are no data from prospective studies focused exclusively on patients 3 
with advanced lung and thymic carcinoids. 4 
 5 
Methods LUNA was a prospective, multicentre, randomised, open-label, 3-arm, phase 2 6 
trial. Patients with advanced, progressive, carcinoid tumours of the lung/thymus were 7 
enrolled from 36 centres in nine countries. Eligible patients were randomised in a 1:1:1 ratio 8 
to receive treatment with long-acting pasireotide (60 mg intramuscularly every 28 days), 9 
everolimus alone (10 mg orally once daily), or in combination, for the core 12-month 10 
treatment period. Patients were stratified by carcinoid type (typical vs atypical) and line of 11 
study treatment (first line vs others). Radiological assessments were performed every 3 12 
months. The primary endpoint was the proportion of patients progression-free at month 9, 13 
which was defined as the proportion of patients with overall lesion assessment at month 9 14 
being complete response (CR), partial response (PR), or stable disease (SD) according to 15 
local Response Evaluation Criteria in Solid Tumours, version 1·1, assessed in the intention-16 
to-treat population. Progression-free survival (PFS) and safety were secondary endpoints. 17 
Safety was assessed in all patients who received at least one dose of study drug and had at 18 
least one post-baseline safety assessment. The trial is registered with ClinicalTrials.gov, 19 
NCT01563354; the extension phase of the study is ongoing. 20 
 21 
Findings Between Aug 16, 2013, and Sept 30, 2014, a total of 124 patients were enrolled; 22 
41 were allocated to long-acting pasireotide (P arm), 42 to everolimus (E arm), and 41 to 23 
combination treatment (EP arm). At month 9, the proportion of patients with an overall lesion 24 
assessment of CR, PR, or SD in the P arm, E arm, or EP arm, were 16/41 (39·0%; 95% CI 25 
24·2–55·5), 14/42 (33·3%; 95% CI 19·6–49·5), and 24/41 (58·5%; 95% CI 42·1–73·7), 26 
respectively. The most common grade 1/2 adverse events with a suspected relationship to 27 
treatment with long-acting pasireotide monotherapy or long-acting pasireotide + everolimus 28 
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were diarrhoea (36·6% [15/41] and 46·3% [19/41], respectively) and hyperglycaemia (41·5% 29 
[17/41] and 65·9% [27/41]); for everolimus, they were stomatitis (61·9% [26/42]) and 30 
diarrhoea (38·1% [16/42]). Eleven patients died during the core 12-month treatment phase 31 
or up to 56 days after the last study treatment exposure date: 2/41 (4·9%) in the P arm, 6/42 32 
(14·3%) in the E arm, and 3/41 (7·3%) in the EP arm. No deaths were suspected to be 33 
related to long-acting pasireotide treatment. One death in the E arm, due to acute kidney 34 
injury associated with diarrhoea, and 2 deaths in the EP arm, due to diarrhoea/urinary sepsis 35 
in one patient and acute renal failure/respiratory failure in the other patient, were suspected 36 
to be related to everolimus treatment. In the latter patient, acute renal failure was not 37 
suspected to be related, while respiratory failure was suspected to be related to everolimus 38 
treatment.  39 
 40 
Interpretation The study met the primary endpoint in all three treatment arms. Safety 41 
profiles were consistent with the known safety profiles of these agents. Further studies are 42 
needed to confirm the antitumour efficacy of the combination of a somatostatin analogue 43 
with everolimus in lung and thymic carcinoids. 44 
 45 
Funding Novartis Pharma AG. 46 
  47 
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Introduction 48 
Neuroendocrine tumours (NET) are relatively rare and heterogeneous tumours that arise 49 
from neuroendocrine cells, often arising in the gastrointestinal (GI) tract, lung, and 50 
pancreas.1 The World Health Organization (WHO) classifies lung and thymic NET into four 51 
major subtypes: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine 52 
carcinoma, and small cell carcinoma.2  53 
Given the lack of prospective clinical trial data from large numbers of patients with advanced 54 
lung and thymic carcinoids, the majority of treatment recommendations are based on results 55 
of studies in GI NET and mixed primary NET populations that include lung and thymic 56 
carcinoids3,4; until recently, there has been an absence of approved drugs for this indication.4 57 
Based on the results of the phase 3 RADIANT-4 study, the mammalian target of rapamycin 58 
(mTOR) inhibitor everolimus recently received US Food and Drug Administration (FDA) and 59 
European Medicines Agency (EMA) approval for the treatment of patients with advanced 60 
(unresectable, locally advanced, or metastatic), progressive, well-differentiated, non-61 
functional NET of lung and GI origin, in addition to the previous approval in pancreatic 62 
NET.5,6 In RADIANT-4, median progression-free survival (PFS) of patients with advanced, 63 
well-differentiated NET of GI or lung origin was significantly improved: 11·0 months for 64 
patients receiving everolimus, compared with 3·9 months among patients receiving placebo 65 
(hazard ratio [HR] 0·48; 95% confidence interval [CI] 0·35–0·67; p<0·0001).7 In a subgroup 66 
analysis of patients with advanced lung carcinoids, everolimus improved median PFS by 5·6 67 
months vs placebo (9·2 vs 3·6 months), as assessed by central review.8 68 
Current European Neuroendocrine Tumor Society (ENETS) consensus guidelines 69 
recommend everolimus as a first-line therapy for progressive, advanced lung carcinoids, 70 
unless a somatostatin analogue (SSA; long-acting octreotide or lanreotide) may be 71 
considered as first-line therapy for tumours with low proliferative activity (i.e., TC) and 72 
somatostatin receptor (SSTR) expression on imaging.4 The recommendation for SSA 73 
treatment is based on the expectation that TC will respond in a similar manner to grade 1 74 
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NET of other sites, such as the GI tract,4 as well as data from a few retrospective analyses 75 
of lung NET.9  76 
Pasireotide is a novel multireceptor ligand SSA with higher affinity for somatostatin receptors 77 
1 (SSTR1), 3 (SSTR3), and 5 (SSTR5) compared with octreotide, but a slightly lower affinity 78 
for SSTR2.10 The antitumour activity of pasireotide (long-acting or short-acting 79 
subcutaneous) has been investigated in phase 2 and 3 trials of patients with advanced NET 80 
who have symptoms refractory to standard long-acting octreotide dosing,11,12 along with a 81 
phase 2 trial of treatment-naive patients with metastatic grade 1 or 2 NET.13 It is 82 
hypothesised that the combined action of long-acting pasireotide on SSTR and inhibition of 83 
insulin-like growth factor 1 receptor (IGF-1R), along with the mTOR inhibitor everolimus, may 84 
control tumour growth more effectively than either treatment alone.14  85 
The phase 2 LUNA trial aimed to assess the efficacy and safety of long-acting pasireotide 86 
and everolimus, administered alone or in combination, in patients with advanced carcinoids 87 
of the lung or thymus. LUNA is the first prospective, randomised clinical trial to focus 88 
exclusively on this specific patient population. 89 
 90 
Methods 91 
Study design and participants 92 
LUNA was a prospective, single-stage, multicentre, randomised, open-label, phase 2 trial 93 
conducted at 36 centres across nine countries (appendix, p 1). The study comprised a 12-94 
month core study period, followed by an extension phase that continued until all patients had 95 
progressed. Adult patients (aged >18 years) with pathologically confirmed advanced 96 
(unresectable or metastatic), well-differentiated, TC or AC of the lung or thymus were 97 
eligible. Histopathologic classification was determined using the WHO 2004 classification of 98 
tumours of the lung, pleura, thymus, and heart;15 cytology by endobronchial ultrasound-99 
guided fine needle aspiration alone was not sufficient for classification. Patients of any 100 
treatment line (naive or pre-treated) and progressive within 12 months according to 101 
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Response Evaluation Criteria In Solid Tumours, version 1·1 (RECIST v1·1) were eligible. 102 
Additional key inclusion criteria included: measurable disease according to computed 103 
tomography (CT) scan or magnetic resonance imaging (MRI) as defined by RECIST v1·1; 104 
WHO performance status ≤2; and adequate bone marrow, liver, and kidney function. Due to 105 
the potential for other SSA or mTOR inhibitors to interfere with the antitumour efficacy 106 
observed in this study, patients were ineligible if they had any of the following: severe 107 
functional disease (ie, carcinoid syndrome) requiring symptomatic treatment with SSA 108 
(judgement made by study clinicians); previous treatment with any long-acting SSA within 1 109 
month of randomisation; or treatment with mTOR inhibitors (sirolimus, temsirolimus, or 110 
everolimus). Patients were also ineligible if they had any of the following: radiotherapy within 111 
4 weeks of randomisation; Cushing’s syndrome requiring treatment within 3 months; 112 
radioligand therapy (peptide receptor radionuclide therapy) within 6 months of 113 
randomisation; hepatic artery embolisation, cryoablation, or radiofrequency ablation of 114 
hepatic metastasis within 3 months of randomisation; participation in a clinical trial testing an 115 
investigational drug within 4 weeks or 5 half-lives (whichever is longer) of randomisation; 116 
uncontrolled diabetes mellitus (haemoglobin A1C of at least 8%) despite adequate therapy; 117 
presence of active or suspected acute or chronic uncontrolled infection; or signs of 118 
recurrence of previous or concomitant malignancies within the last 3 years or requiring active 119 
treatment. The estimated life expectancy of eligible patients was 24-40 months.1,16 120 
The study was conducted in accordance with Good Clinical Practice, the ethical principles of 121 
the Declaration of Helsinki, and local regulations. Institutional review boards, independent 122 
ethics committee, and the research ethics board reviewed and approved the study and all 123 
amendments to the protocol. All patients provided written informed consent. Further details 124 
of the protocol are available on clinicaltrials.gov. 125 
 126 
Randomisation and masking 127 
Patients were randomised (1:1:1) to receive long-acting pasireotide monotherapy (P arm), 128 
everolimus monotherapy (E arm), or everolimus and long-acting pasireotide in combination 129 
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(EP arm). The planned number of patients enrolled was 120, with 40 patients randomised to 130 
each treatment arm. At the screening visit, the investigator or their designee assigned a 131 
unique number to each patient being considered for the study. Once the eligibility of each 132 
patient was confirmed, the investigator or their designee registered the patient using an 133 
interactive voice recognition system into one of the three treatment arms. The randomisation 134 
allocation sequence was generated by an external company (Perceptive Informatics, 135 
Nottingham, UK). Patients were stratified by TC vs AC according to the WHO classification 136 
and line of study treatment (first line of systemic medical treatment vs other). Patients and 137 
investigators were not masked to treatment allocation. 138 
 139 
Procedures 140 
Patients randomised to the P arm received long-acting pasireotide at a dose of 60 mg 141 
intramuscularly (IM) every 28 days; patients randomised to the E arm received everolimus at 142 
a dose of 10 mg taken orally (PO) once daily (QD); and patients randomised to the EP arm 143 
received everolimus and long-acting pasireotide at a dose of 10 mg everolimus PO QD and 144 
60 mg long-acting pasireotide IM every 28 days. Dose reductions and treatment interruptions 145 
for less than 56 days for long-acting pasireotide and less than 28 days for everolimus were 146 
allowed for patients who did not tolerate therapy, or to manage treatment-related adverse 147 
events (AEs). Two dose reductions were allowed for everolimus: from 10 mg per day to 5 mg 148 
per day, with a subsequent reduction to 5 mg every other day. A dose reduction from 60 mg 149 
to 40 mg long-acting pasireotide every 28 days was allowed with a subsequent, but 150 
transient, reduction to 20 mg. Re-escalation to 40 mg was required within 56 days; 151 
otherwise, the patient was discontinued from study. 152 
All patients who underwent randomisation were locally assessed for efficacy by triphasic CT 153 
or MRI every 3 months for the duration of the treatment phase (12 months) and, if the patient 154 
continued into the extension phase, every 3 months thereafter. Safety was monitored by 155 
assessing haematology (baseline and weeks 2, 4, and every 4 weeks (q4w) from weeks 8-156 
52), coagulation (weeks 0, 4, 8, and every 8 weeks (q8w) from weeks 12-52; additionally at 3 157 
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and 7 weeks for those treated with pasireotide), biochemistry (weeks 0, 2, 4, and q4w from 158 
weeks 8-52), fasting glucose (weeks 0, 2-4, and q4w from weeks 7-52), liver function tests 159 
(weeks 0, 2, 4, and q4w from weeks 8-52; additionally at 3 and 7 weeks for those treated 160 
with pasireotide), serum lipid profile (weeks 2, 4, and q4w from weeks 8-52), thyroid function 161 
test (weeks 12, 24, and 52), urinalysis (weeks 0, 2, 4, and q4w from weeks 8-52), 162 
chromogranin-A and 5-hydroxyindoleacetic acid measurement (weeks 12, 24, 36, 48, and 163 
52), electrocardiogram (weeks 0, 3, 8, 16, 28, 40, and 52), gallbladder assessment (only 164 
those treated with pasireotide; weeks 12, 24, 36, 48, 52), and WHO performance status and 165 
vital signs (weeks 0, 2, 4, and q4w from weeks 8-52). Adverse events were assessed 166 
continuously throughout the study and were evaluated for severity grade and duration, 167 
suspected relationship to treatment, whether a dose adjustment, interruption, or 168 
discontinuation was required, outcome, and whether concomitant medication was required. 169 
Study treatment continued for 12 months or until disease progression, intolerable toxicity, 170 
start of new cancer therapy, withdrawal of consent, or discontinuation for any other reason. 171 
Patients who demonstrated clinical benefit, and who were not experiencing unacceptable 172 
toxicity, were allowed to continue treatment in an extension phase until disease progression, 173 
intolerable toxicity, start of new cancer therapy, withdrawal of consent, or discontinuation for 174 
any other reason. The end of the study was defined as the final study visit 2 years after the 175 
start of the last randomised patient, or when all patients had progressed (whichever came 176 
first). All patients were requested to participate in a safety follow-up 56 days after their last 177 
dose of study treatment to assess AEs. 178 
 179 
Outcomes 180 
The primary efficacy endpoint was the progression-free rate at month 9, defined as the 181 
proportion of patients with overall response at month 9, including complete response (CR), 182 
partial response (PR), or stable disease (SD) according to local RECIST v1·1. Patients with a 183 
missing or unknown tumour assessment at month 9, and with CR, PR, or SD at month 11 or 184 
12, were considered as progression free at month 9. Patients with no tumour assessment 185 
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performed in the 211-294 study day period (9 month window) were classified as not 186 
assessed at month 9. Patients with progressive disease, not assessed, or unknown response 187 
at month 9 were classified as non-progression free. 188 
Overall PFS, defined as the time from first study drug administration to tumour progression or 189 
death from any cause according to RECIST v1·1, was a secondary endpoint. Patients who 190 
did not experience a PFS event were censored at the date of the patient’s last adequate 191 
tumour assessment. The probability of patients remaining event free (i.e., no objective 192 
tumour progression or death from any cause) up to the specified timepoint were obtained 193 
from the Kaplan-Meier survival estimates for all treatment groups; the Greenwood formula 194 
was used for confidence intervals of Kaplan-Meier estimates. Tumour shrinkage was 195 
evaluated according to best response per RECIST v1·1. 196 
The safety and tolerability of long-acting pasireotide and everolimus alone or in combination 197 
was assessed by measuring the rate and severity of AEs, which were assessed according to 198 
the Common Terminology Criteria for Adverse Events (CTCAE) version 4·0 (CTCAE grade 5 199 
[death] was not used in this study). The relationship of AEs to treatment was assessed per 200 
investigator decision.  201 
 202 
Statistical analysis 203 
All randomised patients who received at least one dose of study drug constituted the full 204 
analysis set (FAS). Following the intention-to-treat principle, patients were analysed 205 
according to the treatment and stratum they were assigned to at randomisation. Primary 206 
efficacy analyses were assessed on the FAS. The safety set included all patients who 207 
received at least one dose of study drug and had at least one post-baseline safety 208 
assessment. 209 
For the primary endpoint, a Fleming single-stage design was employed for each treatment 210 
arm, where p0 (the null hypothesis) represents the highest proportion of patients progression 211 
free at 9 months that indicated the treatment is clearly ineffective, and p1 (the alternative 212 
hypothesis) represented the minimum required proportion of patients who were progression 213 
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free to show that the treatment is effective. The trial tested the null hypothesis H0 that the 214 
observed proportion of patients who were progression free, p, was less than or equal to p0 215 
against the alternative hypothesis H1 that p was greater than or equal to p1. It consisted of 216 
entering a predetermined number of patients and deciding in favour of p0 or p1 based on the 217 
success rate observed by using an appropriate cutoff between p0 and p1. If the number of 218 
responses was greater than or equal to R+1, p0 was rejected. If the number of responses 219 
was less than or equal to R, p1 was rejected. In this trial, p0 and p1 were set equal to 0·20 220 
and 0·45, respectively, and target alpha and beta were 5% and 10%, respectively. The 221 
number of patients required per treatment arm to determine whether the proportion 222 
responding was less than or equal to p0 or greater than or equal to p1 was determined to be 223 
40. If the number of responses was 13 or more, the hypothesis that p ≤ p0=20% was rejected 224 
with a target alpha error rate of 5% and an actual alpha error rate of 4·3%; if the number of 225 
responses was 12 or less, the hypothesis that p ≥ p1=45% was rejected with an actual beta 226 
error rate of 4%. No dropout percentage was considered in this calculation. 227 
The 95% confidence interval (CI) for the progression-free rate at 9 months was computed 228 
using an exact binomial method. PFS was estimated using the Kaplan-Meier method, with a 229 
95% CI. Tumour shrinkage data were presented as waterfall plots by treatment arm. All data 230 
were analysed using SAS version 9.4. 231 
An independent data monitoring committee reviewed safety-related issues and provided 232 
oversight in study conduct. This study was registered with the EU Clinical Trials Register, 233 
number EudraCT 2011-002872-17, protocol CSOM230DIC03, and with ClinicalTrials.gov, 234 
number NCT01563354. 235 
 236 
Role of the funding source 237 
The study was designed by academic investigators and representatives of the funder 238 
(Novartis Pharma AG). The first draft of the report was prepared by PF, GG, NS, MS, KÖ, 239 
EB, and a medical writer employed by the funder. All authors vouch for the accuracy and 240 
completeness of the data and attest that the study conformed to the protocol and statistical 241 
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analysis plan. The corresponding author had full access to all data in the study and had final 242 
responsibility, along with KÖ and EB, for the decision to submit for publication.  243 
 244 
Results 245 
Between Aug 16, 2013, and Sept 30, 2014, a total of 124 patients with advanced, 246 
progressive, TC or AC of the lung or thymus were enrolled and randomly assigned to receive 247 
treatment with either long-acting pasireotide (P arm; n=41), everolimus (E arm; n=42), or 248 
everolimus and long-acting pasireotide (EP arm; n=41) (figure 1). The core 12-month 249 
treatment phase was completed on Dec 30, 2015. All randomised patients received at least 250 
one dose of study drug and constituted the FAS used for efficacy analyses (n=124). All 251 
patients received at least one dose of medication and had at least one post-baseline safety 252 
assessment, and therefore were all included in the safety set (n=124). Baseline 253 
demographics and disease characteristics at baseline are summarised in table 1. The 254 
median age of the patients was 64 years, 62·1% (77/124) were male, the majority (98·4%; 255 
122/124) were Caucasian and 63·7% (79/124) had an Eastern Cooperative Oncology Group 256 
performance status of 0. The vast majority (116/124; 93·5%) of patients presented with 257 
primary tumours in the lung, around two-thirds (85/124; 68·5%) of patients presented with 258 
AC, and 77·4% (96/124) had non-functional disease. The most common metastatic sites 259 
were the liver (95/124; 76·6%), bone (69/124; 55·6%), lung (48/124; 38·7%), 260 
cervical/thoracic lymph nodes (38/124; 30·6%), and pleura (10/124; 8·1%). Characteristics 261 
were generally well balanced across treatment arms, with the exception of bone metastases, 262 
which were more frequently reported in the long-acting pasireotide treatment arm. 263 
Prior therapies are presented in the appendix (p 2). Approximately a third (40/124; 32·3%) of 264 
patients were treated for advanced disease in the first line. Prior SSA use was well balanced 265 
among the treatment groups; 48·4% (60/124) of patients had received prior SSAs, with the 266 
length of SSA exposure ranging from less than 6 months to 5 or more years. Prior 267 
antineoplastic therapy was more frequently reported in the EP arm. 268 
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During the core 12-month treatment phase, 65·3% (81/124) of randomised patients 269 
discontinued treatment, mainly due to AEs (n=33) and disease progression (n=33) (figure 1). 270 
In the P arm, 68·3% (28/41) of patients discontinued treatment, with 18/28 due to disease 271 
progression and 5/28 due to AEs as the primary reason. In the E arm, 64·3% (27/42) 272 
discontinued treatment, with 15/27 due to AEs as the primary reason and 7/27 due to 273 
disease progression. In the EP arm, 63·4% (26/41) discontinued treatment, with 13/26 due 274 
to AEs as the primary reason and 8/26 due to disease progression. Of the 43 patients who 275 
completed the core phase of the study, 41 entered the extension phase (figure 1).  276 
The proportions of patients with overall lesion assessment at month 9 being CR, PR, or SD 277 
according to RECIST v1·1 (i.e., progression-free) in the P arm, E arm, or EP arm were 16/41 278 
(39·0%; 95% CI 24·2–55·5), 14/42 (33·3%; 95% CI 19·6–49·5), and 24/41 (58·5%; 95% CI 279 
42·1–73·7), respectively (table 2). As noted in table 2, the minimum number of patients 280 
required to be progression free at month 9 in order to consider the treatment as effective 281 
was 13 patients for the P arm, 14 patients for the E arm, and 13 patients for the EP arm. 282 
Overall lesion response at month 9 was mostly SD among the 3 treatment groups; 34·1% 283 
(14/41) in the P arm, 31·0% (13/42) in the E arm, and 48·8% (20/41) in the EP arm. 284 
Progressive disease at 9 months was observed in 7/41 (17·1%), 1/42 (2·4%), and 0/41 (0%) 285 
patients in the P arm, E arm, or EP arm, respectively. Patients with progressive disease, not 286 
assessed, or unknown response at month 9 were classified as non-progression free. The 287 
proportions of patients with no tumour assessment performed at 9 months were classified as 288 
‘not assessed’ but were not excluded from the analysis; 18/41 (43·9%), 25/42 (59·5%), and 289 
17/41 (41·5%) in the P arm, E arm, or EP arm, respectively. This was mostly due to AEs 290 
leading to withdrawal in 3/41 (7·3%), 15/42 (35·7%), and 10/41 (24·4%) of those in the P 291 
arm, E arm, and EP arm, respectively, or due to disease progression prior to month 9 tumour 292 
assessment in 10/41 (24·4%), 4/42 (9·5%), and 2/41 (4·9%), respectively. Overall, 11/36 293 
(30·6%) patients in the P arm, 16/33 (48·5%) in the E arm, and 24/33 (72·7%) in the EP arm 294 
experienced some degree of tumour shrinkage (figure 2). 295 
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The median PFS by investigator-assessed radiological review was 8·51 months (95% CI 296 
5·68–not estimable [NE]), 12·48 months (95% CI 5·55–NE), and 11·79 months (95% CI 297 
11·10–NE) in the P arm, E arm, and EP arm, respectively (figure 3). The probability of 298 
patients remaining event-free (i.e., no objective tumour progression or death from any 299 
cause) until 9 months (table 3) was 49·6% (95% CI 31·9–65·1) for those in the P arm, 56·9% 300 
(95% CI 38·1–71·9) in the E arm, and 79·2% (95% CI 61·1–89·5) in the EP arm.  301 
During the core treatment phase, median patient exposures to long-acting pasireotide in the 302 
P arm and everolimus in the E arm were 38·9 weeks (interquartile range [IQR] 20·00–52·14) 303 
and 26·9 weeks (IQR 10·43–52·00), respectively. In the EP arm, median patient exposure to 304 
long-acting pasireotide was 48·4 weeks (IQR 12·57–52·14) and 49·0 weeks (IQR 12·14–305 
52·14) to everolimus; the median exposure to both drugs combined was 49·0 weeks (IQR 306 
12·57–52·14). The median relative dose intensity of long-acting pasireotide was 100% in 307 
both the P arm (IQR 97·1%–102·0%) and EP arm (IQR 89·2%–107·1%). The median 308 
relative dose intensity of everolimus was 93·6% (IQR 63·0%–100·0%) and 84·1% (IQR 309 
53·6%–100·0%) in the E arm and EP arm, respectively. 310 
Treatment interruptions or dose reductions occurred in 48·8% (20/41) of patients in the P 311 
arm, 66·7% (28/42) of patients in the E arm, 48·8% (20/41) of patients treated with long-312 
acting pasireotide in the EP arm, and 53·7% (22/41) of patients treated with everolimus in 313 
the EP arm. The most common reasons for treatment interruptions or dose reductions were 314 
‘as per protocol’ due to emergent safety concerns (95·0% [19/20], 25·0% [7/28], 65·0% 315 
[13/20], and 36·4% [8/22] of patients treated with long-acting pasireotide in the P arm, 316 
everolimus in the E arm, long-acting pasireotide in the EP arm, and everolimus in the EP 317 
arm, respectively) and ‘any other adverse event’ (40·0% [8/20], 82·1% [23/28], 65·0% 318 
[13/20], and 100·0% [22/22], respectively).  319 
Grade 1/2 treatment-emergent AEs with a frequency of ≥10% in at least one treatment group 320 
are summarised in table 4. Grade 1/2 AEs were reported in all patients in all treatment arms. 321 
The most common grade 1/2 AEs, regardless of drug relationship, reported in the P arm and 322 
the EP arm were hyperglycaemia (43·9% [18/41] and 82·9% [34/41], respectively), diarrhoea 323 
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(39·0% [16/41] and 75·6% [31/41]), and weight decreased (43·9% [18/41] and 56·1% 324 
[23/41]). A higher incidence of grade 1/2 stomatitis (61·9% [26/42]) was reported for patients 325 
treated in the E arm vs the P arm, which was consistent with the established safety profile of 326 
everolimus; the incidence of grade 1/2 stomatitis was lower (31·7% [13/41]) in patients 327 
receiving combination therapy in the EP arm. The most common grade 3 treatment-328 
emergent AEs reported in the P arm were increased gamma glutamyltransferase (12·2% 329 
[5/41]) and dyspnoea (9·8% [4/41]); in the E arm were hyperglycaemia (16·7% [7/42]) and 330 
stomatitis (9·5% [4/42]); and in the EP arm were hyperglycaemia (24·4%, [10/41]), diarrhoea 331 
(17·1%, [7/41]), and fatigue (9·8%, [4/41]) (table 4). Grade 4 treatment-emergent AEs 332 
occurred in 12·2% (5/41) of those in the P arm, 19·0% (8/42) in the E arm, and 9·8% (4/41) 333 
in the EP arm. A complete listing of all grade 3 and 4 treatment-emergent AEs is provided in 334 
the appendix (p 3). 335 
The most common grade 1/2 AEs with a suspected relationship to treatment with long-acting 336 
pasireotide (P arm; EP arm) were diarrhoea (36·6% [15/41]; 22·0% [9/41]), hyperglycaemia 337 
(41·5% [17/41]; 7·3% [3/41]), and weight loss (19·5% [8/41]; 2·4% [1/41]); for everolimus (E 338 
arm; EP arm), they were stomatitis (61·9% [26/42]; 22·0% [9/41]) and diarrhoea (38·1% 339 
[16/42]; 22·0% [9/41]); and for the combination treatment they were hyperglycaemia (65·9% 340 
[27/41]), diarrhoea (46·3% [19/41]), and asthenia (19·5% [8/41]) (appendix, pp 8-13). A 341 
complete listing of all grade 3 and 4 AEs with a suspected relationship to treatment are 342 
provided in the appendix, pp 8-13. 343 
Adverse events requiring study dose adjustment or interruption regardless of study treatment 344 
relationship were reported in 24·4% (10/41) of patients in the P arm, 52·4% (22/42) of 345 
patients in the E arm, and 61·0% (25/41) patients in the EP arm. Treatment-emergent 346 
serious AEs occurred in 39·0% (16/41) of patients in the P arm, 42·9% (18/42) of patients in 347 
the E arm, and 31·7% (13/41) of patients in the EP arm. Eleven patients died during the core 348 
12-month treatment phase or up to 56 days after the last study treatment exposure date: 349 
2/41 (4·9%) in the P arm, 6/42 (14·3%) in the E arm, and 3/41 (7·3%) in the EP arm. In the P 350 
arm, one patient died of disease progression and one died due to pneumonia. Neither death 351 
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was suspected to be related with pasireotide treatment. In the E arm, five deaths were not 352 
considered related to study drug: two due to disease progression and one each due to 353 
respiratory failure, pneumonia, and cardiac failure. One patient died of acute kidney injury 354 
associated with diarrhoea, which was considered related to everolimus therapy. In the EP 355 
arm, one death due to disease progression was not considered related to study drug. One 356 
patient died from diarrhoea and urinary sepsis which was suspected to be associated with 357 
everolimus and one patient died due to acute renal failure and also respiratory failure. For 358 
the latter patient, acute renal failure was not suspected to be related with study treatment, 359 
while respiratory failure was suspected to be related to everolimus. 360 
 361 
Discussion 362 
To our knowledge, LUNA is the first prospective, randomised clinical trial dedicated 363 
specifically to patients with advanced carcinoid tumours of the lung and thymus, 364 
demonstrating the feasibility of conducting clinical trials in this rare NET subpopulation. 365 
Results of the current phase 2 study suggest that long-acting pasireotide, everolimus, or 366 
combination therapy with both agents is associated with antitumour activity, as the null 367 
hypothesis was rejected for all three treatment arms. The 2-year extension phase of this trial 368 
is ongoing, with all patients who benefited from treatment at 12 months; mature data on PFS 369 
will be available when the extension phase of the trial is completed.  370 
To date, the clinical investigation of exclusive pulmonary NET patient populations have been 371 
limited to small retrospective studies.9,17-19 Subgroup analyses of mixed NET populations 372 
have also been conducted, with everolimus being the most studied drug in the setting of lung 373 
NETs.8,20 In the current study, the patient population enrolled had relatively aggressive 374 
tumours; 68·5% of patients were classified as having AC, 67·7% were post first-line therapy, 375 
and 100% had documented disease progression within the previous year according to 376 
RECIST v1·1 criteria. Functional disease was present in 22·6% (28/124) of patients; this is 377 
an interesting additional finding as this is the first and largest prospective clinical trial 378 
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conducted exclusively in this patient population. A recent retrospective US population-based 379 
analysis of patients diagnosed with well-differentiated grade 1 or 2 NET of the lung or other 380 
respiratory organ between 2000-2011 (from the Surveillance, Epidemiology, and End 381 
Results-Medicare database) revealed that carcinoid syndrome was present in 8·0% 382 
(83/1044), 7·9% (19/239), and 15·3% (30/196) of localised, regional, and distant stage 383 
disease.21 Previous estimates of carcinoid syndrome in lung carcinoids have been much 384 
lower (2%) and carcinoid syndrome is rare in thymic carcinoids.22 Other functional 385 
syndromes observed in thoracic carcinoids include Cushing syndrome, caused by ectopic 386 
adrenocorticotropic hormone production, with an incidence of 2% in bronchial carcinoids and 387 
up to 50% in thymic carcinoids, and acromegaly, which occurs rarely in both bronchial and 388 
thymic carcinoids and is caused by ectopic growth hormone–releasing hormone.22 389 
The ‘conservative’ 9-month timepoint was selected to assess the primary endpoint in this 390 
study in order to minimise bias; this timepoint was considered to be acceptable based on the 391 
clinical experience and known biological behaviour of lung NET at the time of study design. 392 
In addition, uncertainties surrounding the management of pulmonary NET with these novel 393 
agents, along with the unknown rate and evolution of functioning syndromes in this NET 394 
subpopulation, were taken into account.  395 
Treatment guidelines as of 2016 recommend everolimus as a first-line therapy for 396 
progressive, advanced lung carcinoids.4 The efficacy of everolimus in non-functional well-397 
differentiated NET of GI and lung origin was recently established in the RADIANT-4 trial.7 A 398 
subgroup analysis of patients with lung NET in RADIANT-4 showed a median PFS of 9·2 399 
months with everolimus vs 3·6 months with placebo by central review, and a median PFS of 400 
13·8 months with everolimus vs 3·5 months with placebo by investigator assessment.8 In 401 
addition, an exploratory analysis of the RADIANT-2 trial reported a median PFS of 13·6 402 
months with everolimus and long-acting octreotide vs 5·6 months with long-acting octreotide 403 
in patients with low or intermediate grade lung NET and carcinoid syndrome.20 In the current 404 
study, the median PFS of patients with functional or non-functional thoracic carcinoids 405 
treated with everolimus alone and in combination with long-acting pasireotide was 12·5 and 406 
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11·8 months, respectively. This confirms the efficacy of everolimus that was demonstrated in 407 
the lung subgroup of the RADIANT-4 study.   408 
Long-acting pasireotide has previously been investigated in clinical trials of patients with 409 
advanced, grade 1 or 2 NET, primarily in patients with primary tumours of the small intestine 410 
or pancreas, with a median PFS of 11·0–11·8 months reported for monotherapy.12,13,23 In this 411 
study of patients with lung or thymic carcinoids, the median PFS of patients treated with 412 
long-acting pasireotide monotherapy was 8·5 months and the combination of everolimus and 413 
long-acting pasireotide was associated with a median PFS of 11·8 months. In the phase 2 414 
COOPERATE-2 study, the addition of long-acting pasireotide to everolimus did not 415 
significantly improve median PFS vs everolimus in patients with non-functional pancreatic 416 
NET (16·8 vs 16·6 months, respectively; hazard ratio 0·99; 95% CI 0·6–1·5, p=0·49). 417 
However, combined treatment with everolimus and long-acting pasireotide demonstrated a 418 
trend toward a higher objective response rate—20·3%, vs 6·2% treated with everolimus 419 
monotherapy.23  420 
The most common grade 1/2 AEs with a suspected relationship to treatment with long-acting 421 
pasireotide monotherapy or everolimus and long-acting pasireotide were diarrhoea (36·6% 422 
and 46·3%) and hyperglycaemia (41·5% and 65·9%). Most AEs were manageable through 423 
dose modification or interruption, with no new safety signals being reported in this study. The 424 
safety profiles observed in the monotherapy and the combination treatment arms were 425 
similar to that of previous studies,8,11,24 indicating the feasibility of combination therapy with 426 
long-acting pasireotide and everolimus. Although discontinuations due to AEs and dose 427 
modifications were frequently reported, the median relative dose intensity remained high in 428 
all treatment groups. Hyperglycaemia has been observed as an AE in other studies with 429 
everolimus and pasireotide monotherapy, albeit at lower frequencies.8,11 The high levels of 430 
hyperglycaemia reported in a phase 1 study24 and in our study of everolimus and long-acting 431 
pasireotide in combination, appears to indicate an additive effect, highlighting the importance 432 
of close monitoring of fasting serum glucose. Achievement of optimal glycaemic control 433 
before initiation of therapy is required.25 Hyperglycaemia is, however, manageable in the 434 
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context of a multidisciplinary centre, thus avoiding the need for treatment discontinuation, 435 
particularly in patients responding to treatment.25 The everolimus dose may be reduced to 5 436 
mg/day or interrupted until the fasting serum glucose has normalized, as per the protocol 437 
used in this study; however, considering the high number of treatment interruptions (52·4%) 438 
or dose reductions (61·1%) due to AEs in this study, it is difficult to state definitively whether 439 
hyperglycaemia will be manageable in all patients without exploratory analyses of the dose-440 
exposure relationship. A limited number of deaths in this study were classified as drug-441 
related per investigator review, but based on the analysis of causes of death, close 442 
observation is recommended for patients undergoing treatment for pulmonary function, as 443 
well as cardiac and kidney function, especially in case of dyspnoea with normal lung imaging 444 
or associated diarrhoea or diabetes. 445 
This study has a number of limitations. The small size and lack of a placebo control arm 446 
limits the comparisons, and the conclusions of the study should be considered exploratory. 447 
No subanalyses of efficacy by primary site (lung vs thymus), carcinoid subtype (TC vs AC), 448 
Ki-67 index (high vs low), or median time from radiological disease progression at baseline 449 
were performed, which may have provided useful information in this rarely studied 450 
population. However, these subanalyses were not appropriate, given the small sample size 451 
and imbalance between groups (eg, only 8 patients with thymic carcinoids), or were not 452 
possible due to the lack of recorded time from disease progression at baseline or Ki-67 453 
indices for each patient. Ki-67 indices were not reported for each patient because the 454 
pathologic assessment in this study was based on the 2004 WHO classification of tumours 455 
of the lung and thymus, which did not include Ki-67.15 It would have been unethical to select 456 
patients based on Ki-67, since the 2004 WHO classification was the only clinical method 457 
recognized by regulatory authorities for the classification of thoracic NET at the time of 458 
enrolment. Another limitation of the study is that only 43/124 (34·7%) patients completed the 459 
12-month core treatment phase. However, the completion and discontinuation rates were 460 
consistent across the treatment groups (figure 1). For the primary endpoint, a single-stage 461 
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Fleming design was employed for each treatment arm; this design has no provision for early 462 
termination if the observed response rate is unacceptably low. Furthermore, for the primary 463 
endpoint (progression-free rate at 9 months), ideally a Kaplan-Meier analysis should be 464 
employed rather than the responder and non-responder analysis that was performed in this 465 
study. In this study, it was not appropriate to alter the primary endpoint to a Kaplan-Meier 466 
analysis after patients had been recruited because the sample size was determined based 467 
on the responder and non-responder analysis. The handling of missing data, such as 468 
patients with a missing tumour assessment at 9 months being classified as non–progression 469 
free, may have led to an underestimation of tumour response rates included in the analysis 470 
of the primary endpoint. However, exclusion of these patients from the primary endpoint 471 
analysis would have led to bias in the results by selecting patients who likely had improved 472 
outcomes. In addition, the lack of blinded central radiological review of tumour response may 473 
have introduced bias in the assessment of response.  474 
In summary, the treatment of patients with advanced carcinoid tumours of the lung and 475 
thymus with long-acting pasireotide alone or in combination with everolimus showed 476 
preliminary evidence of efficacy and an acceptable safety profile. Further studies would be 477 
needed to confirm the antitumour efficacy of combination therapy consisting of an SSA with 478 
everolimus in this subset of patients with NET. Future research may improve prognostic 479 
stratification, identify predictors of response, and determine the anti-secretory impact of the 480 
treatment combination of an SSA with everolimus in the thoracic NET setting. While beyond 481 
the scope of this study, the process toward personalized and precision medicine will be a 482 
priority over the next two decades.   483 
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Research in context 484 
Evidence before this study 485 
We searched PubMed/MEDLINE for published reports on clinical trials in lung and thymic 486 
neuroendocrine tumours (NET), with ‘lung’, ‘thymic’ or ‘thymus’, ‘NET’, and ‘carcinoid’ as our 487 
primary search terms, limiting our findings to include studies evaluating the treatment of 488 
lung/thymic NET or carcinoid tumours. We did not limit our search by date, but only 489 
searched for articles published in English. We identified no prospective clinical trials 490 
specifically investigating the treatment of advanced lung/thymic NET or carcinoids. However, 491 
prospective studies (e.g., RADIANT-2 and RADIANT-4) in mixed NET populations and small 492 
retrospective studies focusing on lung/thymic NET were identified. A subgroup analysis of 493 
the RADIANT-4 trial was presented at the ENETS 13th Annual Conference in 2016, and 494 
reported a clinically meaningful improvement in median progression-free survival (PFS) 495 
following treatment with everolimus in patients with advanced, progressive, well-496 
differentiated, non-functional lung NET. The findings of a subgroup analysis of RADIANT-2 497 
also reported an improvement in median PFS following treatment with everolimus plus 498 
octreotide long-acting repeatable. These exploratory subgroup analyses highlight the 499 
potential benefit of combination therapy with a somatostatin analogue (SSA) and everolimus.  500 
 501 
Added value of this study 502 
Preclinical data suggest that the SSA pasireotide may be associated with more potent 503 
antiproliferative effects than octreotide, thus providing the rationale for combining long-acting 504 
pasireotide with everolimus. To our knowledge, LUNA is the first prospective, randomised, 505 
phase 2 clinical trial investigating an exclusive population of patients with advanced 506 
carcinoid tumours of the lung and thymus. Patients were randomised to treatment with long-507 
acting pasireotide, everolimus, or a combination of the two agents. Our study indicates that 508 
long-acting pasireotide with or without everolimus provides preliminary evidence of 509 
antitumour activity, may improve PFS, and has an acceptable safety profile. Following 510 
confirmation of superiority in phase 3 testing, combination of an SSA with everolimus may be 511 
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useful in the treatment of patients with advanced lung/thymic carcinoid tumours and 512 
demonstrates the feasibility of conducting clinical trials in this rare NET subpopulation.  513 
 514 
Implications of all the available evidence 515 
Prospective clinical data on lung/thymic carcinoid tumours are limited. The results of this 516 
randomised trial indicate that combination therapy of an SSA with everolimus would need 517 
further clinical investigation in this rare subset of patients with NET. Additional well-designed, 518 
adequately powered, randomised controlled clinical trials are required to expand on these 519 
findings and establish the efficacy and safety of this treatment strategy. 520 
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Table 1: Baseline demographics and disease characteristics (full analysis set)  636 
 
P arm 
(n=41) 
E arm 
(n=42) 
EP arm  
(n=41) 
All patients 
(N=124) 
Age, years 
<65  21 (51·2%) 18 (42·9%) 24 (58·5%) 63 (50·8%) 
≥65  20 (48·8%) 24 (57·1%) 17 (41·5%) 61 (49·2%) 
Median 64 66 61 64 
IQR 51–69 61–73 56–69 56-70 
Sex 
Female 15 (36·6%) 19 (45·2%) 13 (31·7%) 47 (37·9%) 
Male 26 (63·4%) 23 (54·8%) 28 (68·3%) 77 (62·1%) 
Race 
Caucasian 40 (97·6%) 42 (100%) 40 (97·6%) 122 (98·4%) 
Black/African 
American 
1 (2·4%) 0 0 1 (0·8%) 
Asian 0 0 1 (2·4%) 1 (0·8%) 
Other 0 0 0 0 
ECOG performance status  
0 28 (68·3%) 24 (57·1%) 27 (65·9%) 79 (63·7%) 
1 11 (26·8%) 17 (40·5%) 14 (34·1%) 42 (33·9%) 
2 2 (4·9%) 1 (2·4%) 0 3 (2·4%) 
Histological grade*  
Typical 14 (34·1%) 12 (28·6%) 13 (31·7%) 39 (31·5%) 
Atypical 27 (65·9%) 30 (71·4%) 28 (68·3%) 85 (68·5%) 
Primary site of cancer 
Lung 38 (92·7%) 39 (92·9%) 39 (95·1%) 116 (93·5%) 
Thymus 3 (7·3%) 3 (7·1%) 2 (4·9%) 8 (6·5%) 
Functional status of tumour 
Functional 12 (29·3%) 7 (16·7%) 9 (22·0%) 28 (22·6%) 
Non-functional 29 (70·7%) 35 (83·3%) 32 (78·0%) 96 (77·4%) 
Current metastatic extent† 
Liver 30 (73·2%) 34 (81·0%) 31 (75·6%) 95 (76·6%) 
Bone 32 (78·0%) 15 (35·7%) 22 (53·7%) 69 (55·6%) 
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Lung 15 (36·6%) 13 (31·1%) 20 (48·8%) 48 (38·7%) 
Cervical/thoracic 
lymph nodes 
14 (34·1%) 15 (35·7%) 9 (22·0%) 38 (30·6%) 
Pleura 2 (4·9%) 2 (4·8%) 6 (14·6%) 10 (8·1%) 
Other‡ 28 (68·3%) 24 (57·1%) 27 (65·8%) 79 (63·7%) 
 637 
Data are n (%) unless otherwise stated. P arm=long-acting pasireotide treatment arm. E 638 
arm=everolimus treatment arm. EP arm=everolimus and long-acting pasireotide treatment 639 
arm. ECOG=Eastern Cooperative Oncology Group. IQR=interquartile range. *Reconciled 640 
rates. During the randomisation process, seven patients were misstratified by the 641 
investigational sites with respect to histologic grade. †Including individual sites with more 642 
than 10% involvement in at least one treatment group. ‡Including skin, thyroid, kidney, 643 
adrenal glands, testis, ovary, breast, ascites (malignant), peritoneum, para-aortic abdominal 644 
lymph nodes, pancreas, spleen, brain, bone marrow, abdomen lymph node, paravertebral 645 
lymph node, subcutaneous lesions, supraclavicular lymph nodes, mediastinum, lung nodes, 646 
left supraclavicular adenopathy, right retrocrural lymph node, or soft tissue on anterior 647 
abdominal wall.   648 
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Table 2: Proportion of patients progression-free at month 9 (full analysis set) 
 
  P arm 
(n=41) 
E arm 
(n=42) 
EP arm  
(n=41) 
  n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Overall lesion response at month 9* 
CR 0 0·0%–
8·6% 
0 0·0%–
8·4% 
0 0·0%–
8·6% 
PR 1 
(2·4%) 
0·1%–
12·9% 
1 
(2·4%) 
0·1%–
12·6% 
1 
(2·4%) 
0·1%–
12·9% 
SD 14 
(34·1%) 
20·1%–
50·6% 
13 
(31·0%) 
17·6%–
47·1% 
20 
(48·8%) 
32·9%–
64·9% 
PD 7 
(17·1%) 
  1 
(2·4%) 
  0   
Unknown†  1 
(2·4%) 
  2 
(4·8%) 
  3 
(7·3%) 
  
Not assessed‡ 18 
(43·9%) 
  25 
(59·5%) 
  17 
(41·5%) 
  
Discontinued 
before Month 9 
20 
(48·8%) 
  24 
(57·1%) 
  16 
(39·0%) 
  
Progression-free 
rate at month 9§ 
16 
(39·0%) 
24·2%–
55·5% 
14 
(33·3%) 
19·6%–
49·5% 
24 
(58·5%) 
42·1%–
73·7% 
Minimum number 
of progression-
free patients to 
reject H0ǁ 
13   14   13   
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P arm=long-acting pasireotide treatment arm. E arm=everolimus treatment arm. EP 
arm=everolimus and long-acting pasireotide treatment arm. CI=confidence interval. 
CR=complete response. PR=partial response. SD=stable disease. PD=progressive disease. 
*Overall lesion response at month 9 is the investigator-reported overall lesion response at 
the week 36 visit. The 95% CI for the responses are computed using an exact binomial 
method. †If progression is not documented and one or more lesions have not been 
assessed or have been assessed using a different method from baseline, then the overall 
lesion response at month 9 is ‘unknown’. ‡If a patient does not have any tumour 
assessments made in the study day 211-294 window, then the overall lesion response at 
month 9 is 'not assessed'. §The progression-free rate at month 9 is defined as the proportion 
of patients with overall lesion assessment at month 9 being CR, PR, or SD according to 
Response Evaluation Criteria in Solid Tumours, version 1·1. Patients with missing or 
unknown month 9 assessment and with CR, PR, or SD at any of the following assessments 
at month 11 or 12 are considered as progression free at month 9. ǁH0: a progression-free 
rate ≤20% is the null hypothesis on the progression-free rates at month 9. The minimum 
number of progression-free patients to reject H0 is calculated according to the Fleming 
single-stage design.  
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Table 3: Progression-free survival per investigator radiological review (full analysis 
set) 
 
P arm 
(n=41) 
E arm 
(n=42) 
EP arm 
(n=41) 
Patients, n (%) 
   
  With events 20 (48·8%) 17 (40·5%) 14 (34·1%) 
  With censorings 21 (51·2%) 25 (59·5%) 27 (65·9%) 
  Censored at day 1 1 (2·4%) 5 (11·9%) 5 (12·2%) 
PFS, months, median (95% CI) 8·5 (5·7–NE) 12·5 (5·6–NE) 11·8 (11·1–NE) 
Event-free probability estimate,* % (95% CI) 
  3-month 83·6% (67·1%–
92·3%) 
91·2% (75·1%–
97·1%) 
88·6% (72·4%–
95·5%) 
  6-month 68·2% (49·8%–
81·1%) 
63·5% (44·7%–
77·4%) 
85·5% (68·6%–
93·7%) 
  9-month 49·6% (31·9%–
65·1%) 
56·9% (38·1%–
71·9%) 
79·2% (61·1%–
89·5%) 
  12-month 35·9% (18·3%–
53·9%) 
50·2% (31·9%–
66·0%) 
39·4% (17·0%–
61·2%) 
P arm=long-acting pasireotide treatment arm. E arm=everolimus treatment arm. EP 
arm=everolimus and long-acting pasireotide treatment arm. PFS=progression-free survival. 
CI=confidence interval. NE=not estimable; *Percentage event-free probability estimate is the 
estimated probability that a patient will remain without objective tumour progression or death 
from any cause up to the specified timepoint. These estimates are obtained from the Kaplan-
Meier survival estimates for all treatment groups; the Greenwood formula is used for 
confidence intervals of Kaplan-Meier estimates. 
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Table 4: Treatment-emergent adverse events, regardless of study drug relationship, by preferred term and treatment (safety set) 
 
P arm 
(n=41) 
E arm 
(n=42) 
EP arm 
(n=41) 
Preferred term* 
Grade 1 or 
2, n (%) 
Grade 3, n 
(%) 
Grade 4, 
n (%) 
Grade 1 or 
2, n (%) 
Grade 3, 
n (%) 
Grade 4, 
n (%) 
Grade 1 or 
2, n (%) 
Grade 3, 
n (%) 
Grade 4, 
n (%) 
Total 
41 (100·0%) 23 (56·1%) 5 (12·2%) 42 (100·0%) 
29 
(69·0%) 
8 (19·0%) 
41 (100·0%) 33 
(80·5%) 
4 (9·8%) 
Hyperglycaemia 18 (43·9%) 3 (7·3%) 0 12 (28·6%) 7 (16·7%) 0 34 (82·9%) 10 
(24·4%) 
0 
Diarrhoea 16 (39·0%) 3 (7·3%) 1 (2·4%) 18 (42·9%) 2 (4·8%) 1 (2·4%) 31 (75·6%) 7 (17·1%) 1 (2·4%) 
Stomatitis 2 (4·9%) 0 0 26 (61·9%) 4 (9·5%) 0 13 (31·7%) 2 (4·9%) 0 
Weight decreased 18 (43·9%) 0 0 17 (40·5%) 1 (2·4%) 0 23 (56·1%) 3 (7·3%) 0 
Asthenia 10 (24·4%) 0 0 12 (28·6%) 1 (2·4%) 0 15 (36·6%) 1 (2·4%) 0 
Abdominal pain 13 (31·7%) 1 (2·4%) 0 4 (9·5%) 0 0 5 (12·2%) 0 0 
Decreased appetite 10 (24·4%) 0 0 13 (31·0%) 2 (4·8%) 0 12 (29·3%) 2 (4·9%) 0 
Cough 6 (14·6%) 0 0 12 (28·6%) 0 0 11 (26·8%) 0 0 
Oedema peripheral 7 (17·1%) 0 0 12 (28·6%) 1 (2·4%) 0 10 (24·4%) 1 (2·4%) 0 
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Anaemia 8 (19·5%) 3 (7·3%) 0 12 (28·6%) 1 (2·4%) 0 8 (19·5%) 2 (4·9%) 0 
Dyspnoea 6 (14·6%) 4 (9·8%) 1 (2·4%) 12 (28·6%) 2 (4·8%) 0 3 (7·3%) 2 (4·9%) 0 
Rash 1 (2·4%) 0 0 11 (26·2%) 3 (7·1%) 0 5 (12·2%) 0 0 
Nausea 10 (24·4%) 0 0 10 (23·8%) 1 (2·4%) 0 8 (19·5%) 0 0 
Fatigue 6 (14·6%) 1 (2·4%) 0 7 (16·7%) 1 (2·4%) 0 10 (24·4%) 4 (9·8%) 0 
Constipation 9 (22·0%) 0 0 6 (14·3%) 1 (2·4%) 0 0 0 0 
Thrombocytopaenia 0 0 0 9 (21·4%) 1 (2·4%) 0 7 (17·1%) 0 0 
Pyrexia 7 (17·1%) 0 0 7 (16·7%) 1 (2·4%) 0 6 (14·6%) 0 0 
Headache 7 (17·1%) 0 0 5 (11·9%) 0 0 6 (14·6%) 0 0 
Back pain 7 (17·1%) 1 (2·4%) 1 (2·4%) 6 (14·3%) 0 0 4 (9·8%) 0 0 
Diabetes mellitus 7 (17·1%) 3 (7·3%) 0 3 (7·1%) 0 0 5 (12·2%) 3 (7·3%) 0 
Blood alkaline phosphatase 
increased 
7 (17·1%) 1 (2·4%) 0 2 (4·8%) 1 (2·4%) 0 2 (4·9%) 1 (2·4%) 0 
Dysgeusia 4 (9·8%) 0 0 4 (9·5%) 0 0 7 (17·1%) 0 0 
Pruritus 2 (4·9%) 0 0 2 (4·8%) 0 0 7 (17·1%) 0 0 
Hypertriglyceridaemia 3 (7·3%) 0 0 7 (16·7%) 0 0 5 (12·2%) 1 (2·4%) 0 
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Vomiting 6 (14·6%) 0 0 4 (9·5%) 0 0 4 (9·8%) 1 (2·4%) 0 
Gamma-glutamyltransferase 
increased 
6 (14·6%) 5 (12·2%) 1 (2·4%) 2 (4·8%) 2 (4·8%) 1 (2·4%) 2 (4·9%) 3 (7·3%) 0 
Productive cough 0 0 0 3 (7·1%) 0 0 6 (14·6%) 0 0 
Chest pain 3 (7·3%) 1 (2·4%) 0 6 (14·3%) 0 0 4 (9·8%) 1 (2·4%) 0 
Hypercholesterolaemia 1 (2·4%) 0 0 6 (14·3%) 0 0 5 (12·2%) 0 0 
Urinary tract infection 3 (7·3%) 2 (4·9%) 0 2 (4·8%) 0 0 5 (12·2%) 0 0 
Hypophosphataemia 1 (2·4%) 0 0 2 (4·8%) 2 (4·8%) 0 5 (12·2%) 1 (2·4%) 0 
Mouth ulceration 0 0 0 2 (4·8%) 1 (2·4%) 0 5 (12·2%) 1 (2·4%) 0 
Epistaxis 0 0 0 5 (11·9%) 0 0 2 (4·9%) 0 0 
Abdominal pain upper 4 (9·8%) 0 0 2 (4·8%) 0 0 3 (7·3%) 0 0 
Hypomagnesaemia 4 (9·8%) 0 0 2 (4·8%) 0 0 3 (7·3%) 0 0 
Dizziness 4 (9·8%) 0 0 2 (4·8%) 0 0 2 (4·9%) 0 0 
Musculoskeletal pain 4 (9·8%) 0 0 1 (2·4%) 0 0 2 (4·9%) 0 0 
Musculoskeletal chest pain 4 (9·8%) 0 0 0 0 0 2 (4·9%) 0 0 
Muscle spasms 4 (9·8%) 0 0 2 (4·8%) 0 0 1 (2·4%) 0 0 
  
 
35 
 
Aspartate aminotransferase 
increased 
4 (9·8%) 0 0 2 (4·8%) 0 0 0 1 (2·4%) 0 
Pneumonia  4 (9·8%) 1 (2·4%) 1 (2·4%) 1 (2·4%) 1 (2·4%) 0 0 0 0 
Chills 4 (9·8%) 0 0 0 0 0 0 0 0 
Hypokalaemia 1 (2·4%) 1 (2·4%) 0 3 (7·1%) 0 0 4 (9·8%) 0 0 
Haemorrhoids 1 (2·4%) 0 0 1 (2·4%) 1 (2·4%) 0 4 (9·8%) 0 0 
Toothache 1 (2·4%) 0 0 1 (2·4%) 0 0 4 (9·8%) 0 0 
Flushing 1 (2·4%) 0 0 0 1 (2·4%) 0 4 (9·8%) 0 0 
Pneumonitis 0 0 0 2 (4·8%) 2 (4·8%) 0 4 (9·8%) 2 (4·9%) 0 
Dysphagia 0 0 0 4 (9·5%) 2 (4·8%) 0 0 0 0 
 
P arm=long-acting pasireotide treatment arm. E arm=everolimus treatment arm; EP arm=everolimus and long-acting pasireotide treatment arm. 
*Presented for those with grade 1 or 2 adverse events occurring with a frequency of ≥10% in at least one treatment group.  
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Figure Legends 
Figure 1: Trial profile 
*Two patients completed the core phase of the study but did not enter the extension phase: 
one patient in the P arm due to worsening clinical condition and one patient in the E arm by 
investigator decision. 
 
Figure 2: Best percentage change from baseline in sum of longest diameters of target 
lesions (full analysis set) 
Percentages are calculated based on n (number of patients included in the analysis). 
Contradiction refers to a percentage change in target lesion available, but contradicted by 
overall lesion response (progressive disease). †N is the number of randomised patients; n is 
the number of patients with valid postbaseline assessments, excluding patients for whom 
target lesion and overall response is ‘unknown’. 
 
Figure 3: Progression-free survival per investigator radiological review (full analysis 
set) 
 
 
